Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Financial Flexibility Index
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Financial Flexibility Index of -1.07x as of June 2026. Free cash flow of $-11.49 Million (operating CF $-11.50 Million minus capex $6.00K) represents -1% of total liabilities ($10.71 Million). Check Contineum Therapeutics, Inc. Class A Com investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Contineum Therapeutics, Inc. Class A Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Contineum Therapeutics, Inc. Class A Common Stock across 5 annual periods. For the full cash flow conversion analysis, see Contineum Therapeutics, Inc. Class A Com cash conversion from operations.
Annual Financial Flexibility Index for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for Contineum Therapeutics, Inc. Class A Common Stock. Explore Contineum Therapeutics, Inc. Class A Com (CTNM) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.52x | $-55.08 Million | $-55.31 Million | $15.65 Million | ▼ -60.9% |
| 2024 | -2.19x | $-32.33 Million | $-32.84 Million | $14.78 Million | ▼ -2295.0% |
| 2023 | 0.10x | $19.76 Million | $19.35 Million | $198.32 Million | ▲ +105.7% |
| 2022 | -1.76x | $-20.00 Million | $-20.12 Million | $11.37 Million | ▲ +39.8% |
| 2021 | -2.92x | $-26.10 Million | $-26.27 Million | $8.93 Million | — |